Tazarotene
- Generic Name
- Tazarotene
- Brand Names
- Arazlo, Duobrii, Fabior, Tazorac
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21NO2S
- CAS Number
- 118292-40-3
- Unique Ingredient Identifier
- 81BDR9Y8PS
- Background
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
- Indication
Used to treat psoriasis, acne and sun damaged skin (photodamage).
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Benign facial lentigines, Facial fine wrinkling, Facial hyperpigmentation, Facial hypopigmentation, Mild Acne vulgaris, Moderate Acne vulgaris
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
- Conditions
- Idiopathic Pulmonary FibrosisIPF
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GRI Bio Operations, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06331624
- Locations
- 🇺🇸
Newport Native MD, Inc., Newport Beach, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Dermatology Consulting Services, PLLC
- Target Recruit Count
- 10
- Registration Number
- NCT06042647
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
- Conditions
- Scalp Psoriasis
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Jinnah Postgraduate Medical Centre
- Target Recruit Count
- 90
- Registration Number
- NCT06015152
- Locations
- 🇵🇰
JPMC, Karachi, Sindh, Pakistan
Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne
- Conditions
- Acne VulgarisErythemaSkin ScarringPost Inflammatory HyperpigmentationPost Inflammatory Pigmentation Change
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dr. Emmy Graber
- Target Recruit Count
- 20
- Registration Number
- NCT05704114
- Locations
- 🇺🇸
The Dermatology Institute of Boston, Boston, Massachusetts, United States
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
- Conditions
- Acne Keloidalis NuchaeAKN
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 30
- Registration Number
- NCT05608499
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Jinnah Postgraduate Medical Centre
- Target Recruit Count
- 202
- Registration Number
- NCT05573425
- Locations
- 🇵🇰
Jinnah Post graduate medical center, Karachi, Sindh, Pakistan
Excimer Laser With Topical Agents in Psoriasis Vulgaris
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT05555797
Efficacy of Tazarotene in Treatment of Verruca Plana
- Conditions
- Warts Flat
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 80
- Registration Number
- NCT05314127
- Locations
- 🇪🇬
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University, Zagazig, Select Region, Egypt
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 402
- Registration Number
- NCT05282771
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: CeraVe, Topical Cream
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Austin Institute for Clinical Research
- Target Recruit Count
- 21
- Registration Number
- NCT05203315
- Locations
- 🇺🇸
Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.